We discovered a new tumor marker MA153 which has been identified as Mu-GlcNAc (Mucin1-N-acetyl-Glucosamine). It can react with monoclonal antibody and a related Aptamer to form the Ma695-Mu-GlcNAc-MA153-A sandwich assay. Taking 1 u/mL as cutoff value, the clinical serum detection results indicated that the tumor specificity of Mu-GlcNAc was 95%, the tumor detection sensitivities were 80%, 74%, 68%, 70%, 75%, 50%, 60%, 55%, 70%，64%, and 60% for breast cancer, pancreatic cancer, liver cancer, lung cancer, esophagus cancer, mouth cancer, colon cancer, bile duct cancer, ovarian cancer, cervix cancer and uterus cancer, respectively. It is concluded that Mu-GlcNAc is a new multi-tumor tumor marker.